Parallax Volatility Advisers
BHVN

Parallax Volatility Advisers’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Parallax Volatility Advisers’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-210,000
Closed -$13.7M – 3423
2020
Q3 		$13.7M Buy
210,000
+195,000
+1,300% +$12.8M 0.01% 860
2020
Q2 		$1.1M Buy
+15,000
New +$798K ﹤0.01% 1705

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Parallax Volatility Advisers's BHVN Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 2,699 shares — an estimated $408K sold.

Parallax Volatility Advisers first reported a position in BHVN in Q4 2017 and held it in 10 quarters. The position peaked at $8.3M in Q2 2020. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Parallax Volatility Advisers reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 2,699 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $408K.
  • Parallax Volatility Advisers first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 10 quarters.
  • Parallax Volatility Advisers's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $8.3M in Q2 2020.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.